USANA Health Sciences, Inc. (USNA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162068,
    "name": "USANA Health Sciences, Inc.",
    "stock_name": "USANA Health Sciences, Inc.",
    "full_name": "USANA Health Sciences, Inc.",
    "name_url": "stocks-analysis/usana-health-sciences-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "19.61",
    "chg": -0.6,
    "chgp": "-2.97%",
    "dir": -1,
    "prev_price": "20.21",
    "mcapval": "565.15",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2310,
    "indexname": "S&P 500",
    "isin": "US90328M1071",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "112.5 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/usana-health-sciences-inc-1162068-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is USANA Health Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-usana-health-sciences-inc-overvalued-or-undervalued-3673355",
        "imagepath": "",
        "date": "2025-11-05 11:09:41",
        "description": "As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 16, an EV to EBITDA of 4.61, and a Price to Book Value of 1.03. In comparison, Chromadex Corp. has a P/E of 39.82 and Nature's Sunshine Products, Inc. shows a P/E of 21.11, both indicating that USANA's valuation is not justified relative to its peers.\n\nThe company's recent performance has been poor, with a year-to-date return of -42.74% compared to the S&P 500's 16.30%, and a staggering -73.15% return over the past five years against the S&P's 109.18%. This stark contrast reinforces the notion that USANA Health Sciences, Inc. is currently overvalued...."
      },
      {
        "title": "Is USANA Health Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-usana-health-sciences-inc-overvalued-or-undervalued-3670550",
        "imagepath": "",
        "date": "2025-11-04 11:15:35",
        "description": "As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating that the stock is overvalued. The company has a P/E ratio of 16, a Price to Book Value of 1.03, and an EV to EBITDA ratio of 4.61. In comparison to peers, Chromadex Corp. has a significantly higher P/E ratio of 39.82, while LifeVantage Corp. presents a more attractive valuation with a P/E of 14.81.\n\nGiven the current metrics and the valuation grade, USANA Health Sciences appears to be overvalued relative to its peers. Although specific return data is not available, the lack of favorable returns compared to the S&P 500 may reinforce the perception of overvaluation...."
      },
      {
        "title": "Is USANA Health Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-usana-health-sciences-inc-overvalued-or-undervalued-3666119",
        "imagepath": "",
        "date": "2025-11-03 11:14:48",
        "description": "As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, as evidenced by its P/E ratio of 16, which is lower than the peer average of 16.23 for similar companies such as Chromadex Corp. and Nature's Sunshine Products, Inc., both of which are also categorized as very expensive. Additionally, USANA's EV to EBITDA ratio stands at 4.61, while its peers like LifeVantage Corp. have a more favorable ratio of 8.26, further highlighting its overvaluation.\n\nIn terms of returns, USANA has significantly underperformed compared to the S&P 500, with a year-to-date decline of 41.07% versus the index's gain of 16.30%. This trend is consistent over longer periods, with a 5-year return of -72.04% compared to the S&P 500's 109.18%. Overall, the combination of valuation metrics and ..."
      },
      {
        "title": "Is USANA Health Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-usana-health-sciences-inc-overvalued-or-undervalued-3664249",
        "imagepath": "",
        "date": "2025-11-02 11:08:13",
        "description": "As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive. The company appears overvalued based on its current financial metrics. The P/E ratio stands at 16, while the EV to EBITDA ratio is 4.61, and the Price to Book Value is 1.03. In comparison, peers like Chromadex Corp. have a P/E ratio of 39.82, and Nature's Sunshine Products, Inc. shows a P/E of 21.11, indicating that USANA's valuation is significantly lower than some competitors, yet still classified as very expensive.\n\nThe stock has underperformed relative to the S&P 500, with a year-to-date return of -41.07% compared to the index's 16.30%, and a three-year return of -59.72% versus 76.66% for the S&P 500. This stark contrast in performance further reinforces the notion that USANA Health Sciences, Inc. is currently overvalued...."
      },
      {
        "title": "USANA Health Sciences Experiences Revision in Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/usana-health-sciences-technical-trend-changes-from-mildly-bearish-to-bearish-amid-stock-decline-3559592",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/USANAHealthScie_technicaldot_3559592.png",
        "date": "2025-09-23 16:11:50",
        "description": "USANA Health Sciences, Inc. has recently revised its market evaluation, with its stock priced at $29.69. Over the past year, the company has faced challenges, showing a significant decline compared to the S&P 500. Technical indicators present a mixed outlook, reflecting potential volatility in its performance."
      },
      {
        "title": "Is USANA Health Sciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-usana-health-sciences-inc-technically-bullish-or-bearish-3558322",
        "imagepath": "",
        "date": "2025-09-23 11:18:50",
        "description": "As of 19 September 2025, the technical trend for USANA Health Sciences, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the Bollinger Bands, both showing bearish signals. The weekly MACD is mildly bullish, but this is overshadowed by the overall bearish indicators from the daily timeframe. Additionally, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -17.28% versus the S&P 500's 13.31%, and a one-year return of -23.08% compared to 16.64% for the index...."
      },
      {
        "title": "Is USANA Health Sciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-usana-health-sciences-inc-technically-bullish-or-bearish-3552179",
        "imagepath": "",
        "date": "2025-09-22 18:05:20",
        "description": "As of 19 September 2025, the technical trend for USANA Health Sciences, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the daily moving averages and the Bollinger Bands both signaling bearish trends. The weekly MACD remains mildly bullish, but this is offset by the bearish signals from the Bollinger Bands and the KST. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. Overall, the technical indicators suggest a bearish outlook, despite some mild bullishness in the MACD on longer time frames. Multi-period return data is not available for comparison with the S&P 500...."
      },
      {
        "title": "Is USANA Health Sciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-usana-health-sciences-inc-technically-bullish-or-bearish-3545435",
        "imagepath": "",
        "date": "2025-09-20 19:11:46",
        "description": "As of 11 September 2025, the technical trend for USANA Health Sciences, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also reflects mild bullishness. However, the daily moving averages are bearish, and the KST shows a mildly bearish trend on the weekly and bearish on the monthly. The Bollinger Bands present a mixed view with weekly bullishness and monthly bearishness. The overall stance is mildly bearish, driven by the bearish daily moving averages and the lack of clear trends in Dow Theory.\n\nIn terms of performance, USANA has underperformed the S&P 500 across multiple periods, with a year-to-date return of -14.07% compared to the S&P 500's 12.22%, and a one-year return of -22.55% versus 17.14%...."
      },
      {
        "title": "Is USANA Health Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-usana-health-sciences-inc-overvalued-or-undervalued-3542144",
        "imagepath": "",
        "date": "2025-09-20 17:45:52",
        "description": "As of 6 August 2025, the valuation grade for USANA Health Sciences, Inc. has moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears to be overvalued, especially when considering its P/E ratio of 16, which is higher than the industry average, and an EV to EBITDA ratio of 4.61, which also suggests a premium valuation compared to peers. Additionally, the Price to Book Value stands at 1.03, further reinforcing the notion that the stock is priced above its intrinsic value.\n\nIn comparison to its peers, Chromadex Corp. has a much higher P/E ratio of 39.82, while LifeVantage Corp. is more reasonably valued at a P/E of 14.81. This highlights USANA's relative overvaluation within the sector. Furthermore, the company's recent stock performance has been disappointing, with a YTD return of -14.07% compared to the S&P 500's positive return of 12.22%, and a staggering..."
      }
    ],
    "total": 15,
    "sid": "1162068",
    "stock_news_url": "https://www.marketsmojo.com/news/usana-health-sciences-inc-1162068"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is USANA Health Sciences, Inc. overvalued or undervalued?

2025-11-05 11:09:41

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 16, an EV to EBITDA of 4.61, and a Price to Book Value of 1.03. In comparison, Chromadex Corp. has a P/E of 39.82 and Nature's Sunshine Products, Inc. shows a P/E of 21.11, both indicating that USANA's valuation is not justified relative to its peers. The company's recent performance has been poor, with a year-to-date return of -42.74% compared to the S&P 500's 16.30%, and a staggering -73.15% return over the past five years against the S&P's 109.18%. This stark contrast reinforces the notion that USANA Health Sciences, Inc. is currently overvalued....

Is USANA Health Sciences, Inc. overvalued or undervalued?

2025-11-04 11:15:35

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating that the stock is overvalued. The company has a P/E ratio of 16, a Price to Book Value of 1.03, and an EV to EBITDA ratio of 4.61. In comparison to peers, Chromadex Corp. has a significantly higher P/E ratio of 39.82, while LifeVantage Corp. presents a more attractive valuation with a P/E of 14.81. Given the current metrics and the valuation grade, USANA Health Sciences appears to be overvalued relative to its peers. Although specific return data is not available, the lack of favorable returns compared to the S&P 500 may reinforce the perception of overvaluation....

Is USANA Health Sciences, Inc. overvalued or undervalued?

2025-11-03 11:14:48

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, as evidenced by its P/E ratio of 16, which is lower than the peer average of 16.23 for similar companies such as Chromadex Corp. and Nature's Sunshine Products, Inc., both of which are also categorized as very expensive. Additionally, USANA's EV to EBITDA ratio stands at 4.61, while its peers like LifeVantage Corp. have a more favorable ratio of 8.26, further highlighting its overvaluation. In terms of returns, USANA has significantly underperformed compared to the S&P 500, with a year-to-date decline of 41.07% versus the index's gain of 16.30%. This trend is consistent over longer periods, with a 5-year return of -72.04% compared to the S&P 500's 109.18%. Overall, the combination of valuation metrics and ...

Is USANA Health Sciences, Inc. overvalued or undervalued?

2025-11-02 11:08:13

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive. The company appears overvalued based on its current financial metrics. The P/E ratio stands at 16, while the EV to EBITDA ratio is 4.61, and the Price to Book Value is 1.03. In comparison, peers like Chromadex Corp. have a P/E ratio of 39.82, and Nature's Sunshine Products, Inc. shows a P/E of 21.11, indicating that USANA's valuation is significantly lower than some competitors, yet still classified as very expensive. The stock has underperformed relative to the S&P 500, with a year-to-date return of -41.07% compared to the index's 16.30%, and a three-year return of -59.72% versus 76.66% for the S&P 500. This stark contrast in performance further reinforces the notion that USANA Health Sciences, Inc. is currently overvalued....

USANA Health Sciences Experiences Revision in Stock Evaluation Amid Market Challenges

2025-09-23 16:11:50

USANA Health Sciences, Inc. has recently revised its market evaluation, with its stock priced at $29.69. Over the past year, the company has faced challenges, showing a significant decline compared to the S&P 500. Technical indicators present a mixed outlook, reflecting potential volatility in its performance.

Is USANA Health Sciences, Inc. technically bullish or bearish?

2025-09-23 11:18:50

As of 19 September 2025, the technical trend for USANA Health Sciences, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the Bollinger Bands, both showing bearish signals. The weekly MACD is mildly bullish, but this is overshadowed by the overall bearish indicators from the daily timeframe. Additionally, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -17.28% versus the S&P 500's 13.31%, and a one-year return of -23.08% compared to 16.64% for the index....

Is USANA Health Sciences, Inc. technically bullish or bearish?

2025-09-22 18:05:20

As of 19 September 2025, the technical trend for USANA Health Sciences, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the daily moving averages and the Bollinger Bands both signaling bearish trends. The weekly MACD remains mildly bullish, but this is offset by the bearish signals from the Bollinger Bands and the KST. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. Overall, the technical indicators suggest a bearish outlook, despite some mild bullishness in the MACD on longer time frames. Multi-period return data is not available for comparison with the S&P 500....

Is USANA Health Sciences, Inc. technically bullish or bearish?

2025-09-20 19:11:46

As of 11 September 2025, the technical trend for USANA Health Sciences, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also reflects mild bullishness. However, the daily moving averages are bearish, and the KST shows a mildly bearish trend on the weekly and bearish on the monthly. The Bollinger Bands present a mixed view with weekly bullishness and monthly bearishness. The overall stance is mildly bearish, driven by the bearish daily moving averages and the lack of clear trends in Dow Theory. In terms of performance, USANA has underperformed the S&P 500 across multiple periods, with a year-to-date return of -14.07% compared to the S&P 500's 12.22%, and a one-year return of -22.55% versus 17.14%....

Is USANA Health Sciences, Inc. overvalued or undervalued?

2025-09-20 17:45:52

As of 6 August 2025, the valuation grade for USANA Health Sciences, Inc. has moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears to be overvalued, especially when considering its P/E ratio of 16, which is higher than the industry average, and an EV to EBITDA ratio of 4.61, which also suggests a premium valuation compared to peers. Additionally, the Price to Book Value stands at 1.03, further reinforcing the notion that the stock is priced above its intrinsic value. In comparison to its peers, Chromadex Corp. has a much higher P/E ratio of 39.82, while LifeVantage Corp. is more reasonably valued at a P/E of 14.81. This highlights USANA's relative overvaluation within the sector. Furthermore, the company's recent stock performance has been disappointing, with a YTD return of -14.07% compared to the S&P 500's positive return of 12.22%, and a staggering...

View All News